 Cumberland Pharmaceuticals Inc. NASDAQ: CPIX, a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor ibuprofen Injection, which was published in the journal Clinical Therapeutics. The manuscript continues an updated integrated safety analysis of Caldolor first presented in 20151. It provides an analysis of nine additional published clinical studies of the product evaluating efficacy, concurrent opioid use, tolerability, pharmacokinetic properties, stress response and postoperative recovery. Results demonstrated Caldolor reaches a higher plasma concentration more quickly than oral ibuprofen, improves post-surgery recovery, decreases surgical stress, and reduces the use of opioids and over-the-counter medication. 